BMC Pharmacology and Toxicology Opens Call for New Editorial Board Members

The open access journal BMC Pharmacology and Toxicology has launched an international call for new Editorial Board Members, a move that reflects both the journal’s rising visibility and the mounting pressure that increased submission volumes place on peer review systems across scientific publishing. The journal, which publishes research on all aspects of chemically defined therapeutic and toxic agents, is seeking established researchers across the full breadth of pharmacology and toxicology to help it scale its editorial capacity while preserving the standards that underpin its reputation. For working scientists, the announcement offers a rare window into how editorial teams at open access journals are constructed, what the role actually demands, and why journals increasingly treat editorial recruitment as a strategic priority rather than an honorary distinction.

The journal’s stated rationale is straightforward: as visibility grows, so does the flow of manuscripts, and an editorial team that cannot expand in step risks slower decisions, overburdened reviewers, and erosion of quality control. BMC Pharmacology and Toxicology is part of the BMC Series, whose stated ethos is open, inclusive and trusted publishing. The journal considers articles spanning experimental and clinical pharmacology, clinical trials, and toxicology, and it explicitly does not weigh editorial decisions on the perceived interest or likely impact of a study. Instead, acceptance criteria hinge on scientific validity, meaning a scientifically sound research question, suitable methods and analysis, and adherence to community-agreed standards relevant to the field. That policy places unusual weight on the judgment of its editors, who must evaluate technical soundness rather than novelty or newsworthiness.

The recruitment drive targets five disciplinary areas in particular: basic pharmacology, clinical pharmacology, computational and in silico modeling studies, drug design, discovery and delivery, and toxicology. The inclusion of computational and modeling expertise is notable, as it signals the journal’s recognition that simulation-based research, molecular docking, pharmacokinetic modeling, and machine learning-assisted drug discovery now constitute a substantial and growing share of submissions in the pharmacological sciences. As in silico methods proliferate, journals need editors who can critically assess algorithmic assumptions, validation strategies, and the biological plausibility of computational predictions, competencies that differ substantially from those required to evaluate a conventional wet-laboratory pharmacology paper.

The eligibility criteria are concrete and demanding. Candidates must have published a minimum of fifteen research papers in reputable, English-language, peer-reviewed journals, and they should have been frequently listed as a corresponding author, in first or last author positions, during the last five years. They must also demonstrate expertise that fits the scope and current needs of the journal. Beyond bibliometric thresholds, the journal emphasizes alignment with its publishing philosophy: suitable candidates are expected to be committed to open access, data sharing, and innovation in scientific publishing, and to act as advocates who represent the journal within the scientific community. This framing positions editorial board membership not as a ceremonial title but as an active service commitment tied to the open science movement.

The operational responsibilities of the role are spelled out with unusual specificity. Editorial Board Members are primarily responsible for assessing manuscripts for their suitability for peer review, selecting reviewers who meet the journal’s requirements, and recommending decisions based on peer reviewers’ reports together with their own assessment, all while adhering to the journal’s editorial policies. The journal expects each board member to handle a minimum of twelve manuscripts per year across a range of disciplines within their broader subject area. That workload, roughly one manuscript per month, is a meaningful recurring commitment for an active researcher, and it explains why the journal pairs the position with formal training and administrative support from its in-house editorial team. Board members report to the journal’s Editor, creating a clear line of accountability within the editorial structure.

For the research community, the significance of such recruitment campaigns extends beyond a single journal. Peer review remains the load-bearing institution of scientific communication, yet the people who sustain it, reviewers and academic editors, are typically unpaid volunteers balancing editorial duties against grant deadlines, teaching, and their own research programs. Studies of the peer review system have repeatedly documented growing reviewer fatigue as global publication output expands faster than the pool of qualified reviewers. Journals that proactively recruit working scientists into editorial roles, and that provide training and administrative infrastructure, are attempting to distribute that burden more sustainably. In pharmacology and toxicology specifically, the stakes are heightened because published findings directly inform drug development, safety evaluation, and clinical practice, making rigorous editorial screening a matter of public health as well as scholarly hygiene.

The journal’s insistence on scientific validity over perceived impact also connects to a broader reform conversation in publishing. Critics of impact-driven editorial filtering argue that journals which reject studies for lacking novelty contribute to publication bias, in which negative results and replication attempts go unpublished and distort the scientific record. By committing to evaluate whether a study asks a sound question and uses appropriate methods, BMC Pharmacology and Toxicology aligns itself with the growing cohort of journals that prioritize methodological rigor and transparency. Editorial Board Members recruited under this ethos are, in effect, being asked to serve as gatekeepers of technical soundness rather than arbiters of fashion, a role that demands broad disciplinary literacy and a willingness to publish findings that may be unglamorous but reliable.

The emphasis on data sharing and open access in the candidate criteria reflects wider structural changes in scientific communication. Funders and institutions increasingly mandate open access publication and data availability, and journals in the BMC Series operate under open access models that make published articles freely readable worldwide. Editors who champion these practices help normalize preprint posting, transparent data deposition, and reproducibility standards within their fields. For early- and mid-career researchers observing how senior scientists behave, visible editorial commitment to open science can shift community norms more effectively than policy statements alone. The journal’s call for committed advocates suggests it understands editorial boards as instruments of cultural change, not merely manuscript processing machinery.

Prospective applicants who meet the criteria are directed to submit their applications through the journal’s online form, with the editorial team reviewing candidates against the published requirements. For researchers in pharmacology and toxicology, the position offers a structured way to shape the standards of their field, gain editorial experience that complements an academic career, and contribute to the peer review infrastructure on which the entire discipline depends. For the journal, expanding the board is a pragmatic response to growth, but it is also a statement about how modern open access publishing intends to scale: by investing in trained, supported, and accountable working scientists rather than allowing review quality to dilute as volume rises. As submission pressures continue to climb across the sciences, the outcome of this recruitment drive will offer a small but telling test of whether that model can hold.

Subject of Research: Editorial board recruitment and peer review operations at the open access journal BMC Pharmacology and Toxicology

Article Title: Join the Editorial Board

Article References: Join the Editorial Board. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: BMC Pharmacology and Toxicology, editorial board, peer review, open access, pharmacology, toxicology, scientific publishing, drug discovery, clinical pharmacology, data sharing, academic journals, editorial recruitment